Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI®" has...
The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, was recently presented at a major global academic conference, drawing significant...
GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therapeutics, for the joint research and development of a novel treatment for geographic atrophy...
BioArctic AB's partner Eisai announced that the Department of Health in Hong Kong has approved Leqembi® (brand name in Hong Kong, generic name: lecanemab) for treatment of Alzheimer's disease (AD). Treatment with Leqembi should be initiated in...
PharmAbcine, Inc. a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today the decision to advance PMC-403, its candidate treatment for neovascular age-related macular degeneration...
Hyundai Bioscience (CEO Oh Sang-gi), which is preparing for a dengue fever basket clinical trial in Brazil, announced on the 24th that it has successfully developed a 'multi-treatment drug for mosquito-borne viral infections, including dengue...
BioArctic AB's partner Eisai announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for less frequent monthly lecanemab-irmb (U.S. brand name: Leqembi)...
Onconic Therapeutics, a leading biotechnology company in Korea, announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved JAQBO (zastaprazan citrate) for the treatment of erosive gastroesophageal reflux disease (GERD) in...
Aptamer Sciences Inc. (KOSDAQ, 291650) announced the filing of an Investigational New Drug (IND) application for the phase 1 clinical trial of AST-201. AST-201, the company's pioneering candidate in its pipeline, is an ApDCTM (Aptamer-Drug...
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company has obtained prequalification (PQ) certification from the World Health Organization (WHO). For...
